Related Articles

Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions.

Adv Exp Med Biol. 2021;1297:27-42

Authors: Vázquez M, García-Carnelli C, Maldonado C, Fagiolino P

Over the past few years, considerable attention has focused on cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), the two major constituents of Cannabis sativa, mainly due to the promising potential medical uses they have shown. However, more information on the fate of these cannabinoids in human subjects is still needed and there is limited research on the pharmacokinetic drug-drug interactions that can occur in the clinical setting and their prevalence. As the use of cannabinoids is substantially increasing for many indications and they are not the first-line therapy in any treatment, health care professionals must be aware of drug-drug interactions during their use as serious adverse events can happen related with toxic or ineffective outcomes. The present chapter overview summarizes our current knowledge on the pharmacokinetics and metabolic fate of CBD and THC in humans and discusses relevant drug-drug interactions, giving a plausible explanation to facilitate further research in the area.

PMID: 33537935 [PubMed – in process]

Source: ncbi

Partage le savoir
Categories: Medical

error: Content is protected !!